Andere Sprachen NeuroMetrix, Inc.

Aktien

A3E17K

US6412558800

NURO

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 18.04.2024			% 5 Tage	% 1. Jan.
3,65 ^USD	+2,24 %		-5,19 %	+1,39 %

14.03.	NeuroMetrix, Inc. kündigt Veröffentlichung einer Studie an, die zeigt, dass DPNCheck diabetische periphere Neuropathie genau diagnostiziert	CI
27.02.	Ephraim Fields legt seine Ansichten über NeuroMetrix offen	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)	20.03.
NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy	14.03.
NeuroMetrix, Inc. Announces Publication of Study Demonstrating That DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy	14.03.
NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia	13.03.
Ephraim Fields Discloses his Views on NeuroMetrix	27.02.
RS Fund Discloses its Views on NeuroMetrix	26.02.
NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights	22.02.
NeuroMetrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22.02.
NeuroMetrix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22.02.
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call	15.02.
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value	13.02.
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value	13.02.
NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024	08.01.
NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)	12.12.
Neurometrix, Inc. Reports Encouraging Results from Pilot Clinical Trial of Quell®? in Post-Acute Covid-19 Syndrome (Long Covid)	12.12.
NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy	06.12.
NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)	05.12.
NeuroMetrix, Inc. Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy	05.12.
Sector Update: Health Care Stocks Advance in Late Afternoon Trading	20.11.
Sector Update: Health Care Stocks Advance in Afternoon Trading	20.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen NeuroMetrix, Inc.

Aktien

A3E17K

US6412558800

NURO

Andere Sprachen

Filter